Cambrex has posted a positive set of Q2 results, recording an operating income of $9m (€6.3m), but warned that the second half of the year is likely to be down on the corresponding six months of last year.The results cite the timing of orders for two long term active pharmaceutical ingredient supply contracts as helping Cambrex’s operating income increase by 61 per cent.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
These gains were partially offset by lower sales of generic APIs. Total sales were down by 9.8 per cent compared to Q2 2008 but Cambrex believes this is a consequence of unfavourable foreign exchange. Excluding the influence of the stronger US dollar, Cambrex claims that sales increased by 2.1 per cent.
StockEinstein.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified directly to their in-box.
This is a free service available only to our subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
During 2009 our alerts have resulted in an average price gain of 80%+.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
